title: NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
abstract: BACKGROUND
  NY-ESO-1 antibodies are specifically observed in patients with NY-ESO-1-expressing tumours. We analysed whether the NY-ESO-1 humoral immune response is a useful tumour marker of gastric cancer.
  
  
  METHODS
  Sera from 363 gastric cancer patients were screened by enzyme-linked immunosorbent assay (ELISA) to detect NY-ESO-1 antibodies. Serial serum samples were obtained from 25 NY-ESO-1 antibody-positive patients, including 16 patients with curative resection and 9 patients who received chemotherapy alone.
  
  
  RESULTS
  NY-ESO-1 antibodies were detected in 3.4% of stage I, 4.4% of stage II, 25.3% of stage III, and 20.0% of stage IV patients. The frequency of antibody positivity increased with disease progression. When the NY-ESO-1 antibody was used in combination with carcinoembryonic antigen and CA19-9 to detect gastric cancer, information gains of 11.2% in stages III and IV, and 5.8% in all patients were observed. The NY-ESO-1 immune response levels of the patients without recurrence fell below the cutoff level after surgery. Two of the patients with recurrence displayed incomplete decreases. The nine patients who received chemotherapy alone continued to display NY-ESO-1 immune responses.
  
  
  CONCLUSIONS
  When combined with conventional tumour markers, the NY-ESO-1 humoral immune response could be a useful tumour marker for detecting advanced gastric cancer and inferring the post-treatment tumour load in seropositive patients.
authors: Department of Gastroenterological Surgery, Osaka University, Osaka, Japan.
authors: S
authors: S
authors: Fujiwara
authors: H
authors: H
authors: Wada
authors: J
authors: J
authors: Kawada
authors: R
authors: R
authors: Kawabata
authors: T
authors: T
authors: Takahashi
authors: J
authors: J
authors: Fujita
authors: T
authors: T
authors: Hirao
authors: K
authors: K
authors: Shibata
authors: Y
authors: Y
authors: Makari
authors: S
authors: S
authors: Iijima
authors: H
authors: H
authors: Nishikawa
authors: A A
authors: AA
authors: Jungbluth
authors: Y
authors: Y
authors: Nakamura
authors: Y
authors: Y
authors: Kurokawa
authors: M
authors: M
authors: Yamasaki
authors: H
authors: H
authors: Miyata
authors: K
authors: K
authors: Nakajima
authors: S
authors: S
authors: Takiguchi
authors: E
authors: E
authors: Nakayama
authors: M
authors: M
authors: Mori
authors: Y
authors: Y
authors: Doki
mesh_terms: D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood*; D000951:Antigens, Neoplasm / Q000276:immunology*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D018450:Disease Progression; D005260:Female; D006801:Humans; D056724:Immunity, Humoral; D008297:Male; D008565:Membrane Proteins / Q000276:immunology*; D008875:Middle Aged; D011379:Prognosis; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology; D047368:Tumor Burden
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; C104948:CTAG1B protein, human; D002272:Carcinoembryonic Antigen; D008565:Membrane Proteins; C578959:carbohydrate antigen 199, human
references: Am J Gastroenterol. 1996 Jan;91(1):49-53
references: 8561143
references: Cancer Immun. 2009 Oct 01;9:8
references: 19791734
references: Oncology. 2004;67(1):19-26
references: 15459491
references: Eur J Cancer. 2006 Aug;42(12):1897-903
references: 16831544
references: Br J Urol. 1987 Jul;60(1):69-73
references: 2441790
references: Int J Cancer. 2011 Dec 15;129(12):2836-46
references: 21448901
references: Ann Ital Chir. 2011 Mar-Apr;82(2):125-9
references: 21682102
references: Br J Cancer. 2000 Dec;83(12):1664-73
references: 11104564
references: Gastric Cancer. 2003;6(3):142-5
references: 14520526
references: Int J Cancer. 2012 Feb 1;130(3):584-92
references: 21413013
references: Clin Cancer Res. 1995 Dec;1(12):1463-9
references: 9815945
references: Cancer. 2000 Oct 15;89(8):1677-83
references: 11042560
references: Cancer Immun. 2003 Jul 31;3:10
references: 12889868
references: Lancet. 2002 Aug 31;360(9334):683-9
references: 12241875
references: Hepatogastroenterology. 1986 Oct;33(5):201-5
references: 2433199
references: Urology. 1986 Dec;28(6):472-9
references: 2431533
references: Jpn J Clin Oncol. 2009 Jan;39(1):71-2
references: 19103673
references: Int J Oncol. 2006 Oct;29(4):973-80
references: 16964393
references: JAMA. 1976 May 3;235(18):1975-9
references: 56468
references: J Exp Med. 1998 Apr 20;187(8):1349-54
references: 9547346
references: Cancer Lett. 2006 May 8;236(1):64-71
references: 15992994
references: Tunis Med. 2011 Oct;89(10):779-83
references: 22076902
references: Ann Oncol. 2007 May;18(5):868-73
references: 17347129
references: J Surg Oncol. 1993 Aug;53(4):235-8
references: 8341054
references: Surgery. 2010 Jul;148(1):96-102
references: 20096433
references: Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8
references: 21933959
references: J Clin Oncol. 2011 Nov 20;29(33):4387-93
references: 22010012
references: Nat Rev Cancer. 2012 Mar 22;12(4):252-64
references: 22437870
references: Int J Cancer. 2008 Nov 15;123(10):2362-9
references: 18729190
references: Cancer. 1995 Mar 15;75(6 Suppl):1497-502
references: 7889481
references: Int J Cancer. 1999 Oct 22;84(5):506-10
references: 10502728
references: Adv Cancer Res. 2006;95:1-30
references: 16860654
references: Cancer Immun. 2007 Apr 19;7:9
references: 17441676